10-K: Century Therapeutics Announces 2024 Results, Pipeline Prioritization

Century Therapeutics reports its 2024 financial results and outlines a strategic shift in its preclinical pipeline, focusing on iT cell therapies.

Summary

• Century Therapeutics, a clinical-stage biotechnology company, released its 10-K filing for the year ended December 31, 2024.
• The company is focused on developing allogeneic pluripotent stem cell therapies for autoimmune diseases and cancer.
• CNTY-101, a CAR-iNK cell therapy, is currently in a Phase 1 clinical trial for B-cell mediated autoimmune diseases.
• The ELiPSE-1 Phase 1 clinical trial of CNTY-101 for lymphoma was discontinued for strategic reasons.
• The company is prioritizing three preclinical programs based on its iT cell platform: CNTY-308, CNTY-341, and a solid tumor CAR iT program.
• The company believes its existing cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditures requirements into the fourth quarter of 2026.
• The net losses for the years ended December 31, 2024 and 2023 were $126.6 million and $136.7 million, respectively.
• As of December 31, 2024, the company had cash, cash equivalents, and investments of $220.1 million.
• The company is developing manufacturing capabilities in a 53,000 square foot facility in Branchburg, New Jersey.
• Bristol-Myers Squibb terminated its collaboration agreement with Century Therapeutics, effective March 12, 2025.
• The company is subject to various healthcare and privacy laws and regulations.
• As of March 1, 2025, the company had 150 full and part-time employees, with 131 engaged in research and development activities.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a promising technology platform and is prioritizing its pipeline, it is also facing significant financial challenges and has experienced setbacks in its clinical development programs. The termination of the collaboration agreement with Bristol-Myers Squibb is a negative development, but the company is still pursuing other opportunities.

Positives

• The company is focusing on a promising area of medicine with allogeneic pluripotent stem cell therapies.
• The company has a comprehensive, genetically engineered allogeneic cell therapy platform.
• The company is prioritizing three preclinical programs based on its iT cell platform.
• The company believes its existing cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditures requirements into the fourth quarter of 2026.

Negatives

• The company has incurred significant operating losses since its inception and expects to continue to incur significant losses for the foreseeable future.
• The company has never generated revenue from product sales and may never achieve or maintain profitability.
• The company is highly dependent on the success of its lead product candidate, CNTY-101, and its other product candidates.
• The company discontinued the ELiPSE-1 Phase 1 clinical trial of CNTY-101 for lymphoma.
• Bristol-Myers Squibb terminated its collaboration agreement with Century Therapeutics, effective March 12, 2025.

Risks

• The company's limited operating history may make it difficult to evaluate its business.
• The company may never achieve or maintain profitability.
• The company is dependent on the success of its lead product candidate, CNTY-101, and its other product candidates.
• The company faces challenges in developing, commercializing, and manufacturing its product candidates.
• The company may be required to relinquish important rights to and control over the development and commercialization of its product candidates to any future collaborators.
• The trading price of the shares of the company's common stock has been highly volatile, and purchasers of the company's common stock could incur substantial losses.

Future Outlook

The company believes its existing cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditures requirements into the fourth quarter of 2026. The company anticipates that its expenses and operating losses will increase substantially over the foreseeable future.

Management Comments

• The company is leveraging its expertise in cellular reprogramming, differentiation, genetic engineering, and manufacturing to develop therapies with the potential to provide enhanced clinical outcomes compared to existing cell therapy technologies and available therapeutic options.
• The company's vision is to become a premier, fully integrated biotechnology company by developing and ultimately commercializing off-the-shelf allogeneic cell therapies that dramatically and positively transform the lives of patients suffering from life-threatening autoimmune diseases and cancers.

Industry Context

The biotechnology and pharmaceutical industries have made substantial investment in recent years in the rapid development of novel immunotherapies for the treatment of a range of pathologies, including cancers, and autoimmune disorders, making this a highly competitive market.

Comparison to Industry Standards

• Comprehensive data is available from the use of cellular therapy in R/R B cell lymphoma.
• In patients treated with FDA-approved CD19 CAR T therapies with 24 months of follow-up data, overall response rates ranged from 53-83% and complete response rates from 39-65%.
• Long-term event-free survival, or EFS, rates of 38-43% indicate an approximate curative rate of approximately 40%.
• Two CD19 CAR-T cell products have also been approved in the second-line setting (patients who were refractory to first-line therapy or relapsed within 12 months) due to a longer EFS compared to autologous stem cell transplant in randomized trials.
• This background, as well as data from products currently under development, provides benchmarks for assessment of newer cell therapies such as CNTY-101, CNTY-308, and CNTY-341.

Related Party Transactions

• The company has license and collaboration agreements with FUJIFILM Cellular Dynamics, Inc. (FCDI), a shareholder of Century.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and strategic decisions.
• Employees may be impacted by changes in the company's pipeline and resource allocation.
• Patients may be impacted by the development of new therapies for autoimmune diseases and cancer.

Next Steps

• Advance CNTY-101 clinical development and understand the value of CD19 CAR NK therapy in autoimmunity, and evaluate initial POC in oncology.
• Develop transformative next generation allogeneic therapies for autoimmune diseases and oncology using our industry leading iT cell platform.
• Leverage our own manufacturing infrastructure, product, and process understanding and scale-up technologies to minimize manufacturing risk.
• Selectively evaluate strategic partnerships to enable greater patient access.

Key Dates

Keywords

iPSC, cell therapy, CNTY-101, allogeneic, autoimmune diseases, cancer, clinical trials, biotechnology, immuno-oncology, CAR-iNK cells, CAR-T cells